Skip to content
Chevron Corporation (NYSE: CVX) is expected to generate free cash flow of around $1.3 billion in 2020 and $10.1 billion in 2021, and its "preserved financial capacity" is a "significant strategic advantage," according to MKM Partners.The Chevron Analyst: John Gerdes initiated coverage of Chevron with a Buy rating and $121 price target. The Chevron Takeaways: Between 2022 and 2025, the company could generate about 3% compounded annual growth in its cash flow per share and around 12% average annual free cash flow yield, Gerdes said in a Wednesday initiation note. "As a consequence of a 65%-70% higher cash operating margin and competitive equity production-normalized capital intensity, Chevron's full-cycle return of 190%-195% is significantly above the industry median of 125%," the analyst said. Chevron is acquiring Noble Energy, Inc. (NASDAQ: NBL) in an all-stock transaction.The acquisition, which is expected to close in early October, "provides complementary assets in the Delaware Basin and...
International Business Machines Corporation's (NYSE:IBM) price-to-earnings (or "P/E") ratio of 13.4x might make it......
The Trump Administration is laying out a plan to launch an antitrust suit against Google. Yahoo Finance’s Brian Sozzi and Alexis Christoforous discuss the lawsuit, and President Trump’s railing against social media giants with Econ One Managing Director, Hal Singer....
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may......
Lou Lentine, Echelon CEO, joins Yahoo Finance’s The First Trade with Alexis Christoforous and Brian Sozzi to discuss the controversy around its product on Amazon, its offerings and much more....
For those that thought the extreme market volatility was behind us, think again. This month, another burst of volatility was brought on by concerns about the U.S. economic recovery, hefty valuations, and a second wave of COVID-19. While challenging at times, Wall Street pros believe the healthcare space is becoming more exciting, with several long-term tailwinds on the horizon.As healthcare stocks tend to be riskier in nature, we narrowed our search to include only the best of the best, according to the analyst community.TipRanks’ database revealed three such stocks that won’t break the bank; each one trades for less than $5 per share and has earned a “Strong Buy” consensus rating from the Street’s pros. Not to mention triple-digit upside potential is on the table here.VYNE Therapeutics (VYNE)Using its Molecule Stabilizing Technology (MST) platform, VYNE Therapeutics hopes to solve some of the most difficult therapeutic challenges. Given the strong performance of one...
Tesla’s much anticipated Battery Day certainly hasn’t done much to charge up its stock, but here's why analysts still think the future is bright....
